A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
OBJECTIVE: We assessed the impact of medical weight management (MWM; lifestyle modification ± obesity medications) on major adverse cardiovascular events (MACE) compared to metabolic and bariatric surgery (MBS) and usual care (UC). METHODS: We retros…
This review covers a seminal study of the relation between exposure to the glucagon-like peptide 1 (GLP-1) agonist semaglutide and incident non-arteritic anterior ischaemic optic neuropathy (NAION) in a neuro-ophthalmology clinic setting, subsequent…
: Acetyl-CoA carboxylase (ACC) inhibitors block the initial step of de novo lipogenesis and potentially ameliorate liver pathology in nonalcoholic fatty liver disease (NAFLD). However, increased expression of glycerol-3-phosphate acyltransferase 1 re…
Therapeutic proteins and peptides have revolutionized modern biomedicine, but their oral delivery is limited by gastrointestinal degradation and barriers. Small extracellular vesicles (sEVs), which are resistant to biochemical degradation and capable…
BACKGROUND: Semaglutide is a GLP-1 receptor agonist that provides a reduction in glycated hemoglobin and weight. The objective was to evaluate whether the use of semaglutide, in individuals with overweight or obesity, reduces cardiovascular outcomes…
OBJECTIVE: This systematic review aimed to assess the efficacy and safety of GLP-1 RAs in adults with obesity or overweight, by comparing different GLP-1 RAs, identifying the most effective agents, and evaluating adverse effects. METHODS: We systemat…
PURPOSE: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes. PATIENTS AND METHODS: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients ag…
BACKGROUND AND AIM: On January 17th 2025, the European Medicines Agency started a review on semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy (NAION); we gained insight into this potential association by appraising post-marketing report…
BACKGROUND: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, for weight management has raised new considerations in aesthetic surgery. While these drugs offer significant preoperative weight loss benefits,…
BACKGROUND: Type 2 diabetes (T2D) is the leading cause of chronic kidney disease (CKD) and kidney failure globally. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, reduces the risk of major kidney, cardiovascular and mortality outcom…
The introduction of semaglutide, a glucagon-like-1 receptor agonist (GLP-1ra) as a weight-loss medication, has attracted considerable public and medical attention, reporting weight reductions of up to 15 %. However, its rapid adoption highlights the…
This retrospective case series investigates the impact of GLP-1 receptor agonists (GLP-1RAs) on whole-gut gastrointestinal motility using wireless motility capsule testing. We analyzed 10 patients on GLP-1RAs who underwent wireless motility capsule t…
BACKGROUND Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained popularity in recent years. Consequently, Semaglutide prescription rates have increased for both its indicated and off-label uses. A possible link between GLP-1 RAs and suic…
PURPOSE OF THE REVIEW: Epicardial adipose tissue (EAT), the visceral fat of the heart, is highly inflammatory fat depot with pro-inflammatory transcriptome and proteosome. EAT contributes to the development and progression of coronary artery disease…
The prevalence of obesity continues to increase worldwide. Obesity is associated with an increased risk of cardiometabolic and other diseases, reduced quality of life and shortened life expectancy. Highly effective therapies are required to achieve m…